UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas

Human pathology, 2007-04, Vol.38 (4), p.564-569

2007

Volltextzugriff (PDF)

Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era

The Journal of urology, 2005-01, Vol.173 (1), p.70-72

2005

Volltextzugriff (PDF)

1485 USE OF PDE-5 INHIBITORS (PDE-5I) BEFORE RADICAL PROSTATECTOMY (RP) AND NERVE SPARING STATUS (NSS) PREDICTS LONG TERM ERECTILE FAILURE

The Journal of urology, 2012-04, Vol.187 (4S)

2012

Volltextzugriff (PDF)

ROLE OF BIOPSY IN THE MANAGEMENT OF SMALL RENAL MASSES

The Journal of urology, 2009, Vol.181 (4S), p.246-246

2009

Volltextzugriff (PDF)

Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial

The Journal of urology, 2024-02, Vol.211 (2), p.205-213

2024

Volltextzugriff (PDF)

Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer

Modern pathology, 2003-03, Vol.16 (3), p.198-205

2003

Volltextzugriff (PDF)

Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial

The Journal of urology, 2024-07, Vol.212 (1), p.21

2024

Volltextzugriff (PDF)

Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial

The Journal of urology, 2024-07

2024

Volltextzugriff (PDF)

MP09-08 PATIENT-REPORTED PREFERENCE BETWEEN TRANSRECTAL AND TRANSPERINEAL PROSTATE BIOPSY

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

Implementation and Assessment of No Opioid Prescription Strategy at Discharge After Major Urologic Cancer Surgery

JAMA surgery, 2023-04, Vol.158 (4), p.378

2023

Volltextzugriff (PDF)

Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study)

Prostate cancer and prostatic diseases, 2021-09, Vol.24 (3), p.688-696

2021

Volltextzugriff (PDF)

Tissue-marking scheme for a cost-effective extended prostate biopsy protocol

Urologic oncology, 2009, Vol.27 (1), p.21-25

2009

Volltextzugriff (PDF)

Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas

Human pathology, 2005-11, Vol.36 (11), p.1204-1209

2005

Volltextzugriff (PDF)

PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy

Urologic oncology, 2008-03, Vol.26 (2), p.166-170

2008

Volltextzugriff (PDF)

Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer

Clinical cancer research, 2003-12, Vol.9 (17), p.6357-6362

2003

Volltextzugriff (PDF)

HER-2/ neu gene amplification status in prostate cancer by fluorescence in situ hybridization

Human pathology, 1997-07, Vol.28 (7), p.827-833

1997

Volltextzugriff (PDF)

Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e24151-e24151

2018

Volltextzugriff (PDF)

Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12070-12070

2018

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2007-10, Vol.178 (4), p.1211-1211

Fisher, Hugh A.G.

2007

Volltextzugriff (PDF)

Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5061-5061

2018

Volltextzugriff (PDF)

Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.348-348

2018

Volltextzugriff (PDF)

Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4522-4522

2016

Volltextzugriff (PDF)

Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.187-187

2016

Volltextzugriff (PDF)

Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.371-371

2016

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas

Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era

1485 USE OF PDE-5 INHIBITORS (PDE-5I) BEFORE RADICAL PROSTATECTOMY (RP) AND NERVE SPARING STATUS (NSS) PREDICTS LONG TERM ERECTILE FAILURE

ROLE OF BIOPSY IN THE MANAGEMENT OF SMALL RENAL MASSES

Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial

Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer

Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial

Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial

MP09-08 PATIENT-REPORTED PREFERENCE BETWEEN TRANSRECTAL AND TRANSPERINEAL PROSTATE BIOPSY

Implementation and Assessment of No Opioid Prescription Strategy at Discharge After Major Urologic Cancer Surgery

Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study)

Tissue-marking scheme for a cost-effective extended prostate biopsy protocol

Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas

PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy

Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer

HER-2/ neu gene amplification status in prostate cancer by fluorescence in situ hybridization

Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs

Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs

Editorial Comment

Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC)

PD60-01 CASTRATE RESISTANT TMPRSS2: ERG FUSION POSITIVE AND TMPRSS2: ERG WILD TYPE REFRACTORY ACINAR AND NEUROENDOCRINE PROSTATE CANCER DIFFER IN GENOMIC SIGNATURES AND OPPORTUNITIES FOR TARGETED AND IMMUNOTHERAPIES

Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC)

Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load

Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate

Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection

Suchergebnisse filtern